Continuing Education Activity
Immunotherapy is used to upregulate or downregulate the immune system to achieve a therapeutic effect in immunological mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy. This activity will highlight the various types of immunotherapy, including mechanisms of action, adverse event profiles, and other key factors, e.g., dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions pertinent for members of the interprofessional team in the management of patients with conditions that can benefit from receiving immunotherapy.
- Identify different categories of immunotherapy.
- Summarize indicated conditions for each type of immunotherapy.
- Review some of the contraindications to various forms of immunotherapy.
- Explain interprofessional team strategies for improving care coordination and communication to advance immunotherapy, improve outcomes, and minimize adverse events.
Immunotherapy is the use of drugs (e.g., immunosuppressors), biologicals (e.g., cytokines, monoclonal antibodies, and antisera), vitamins and minerals (e.g., zinc, vitamin C, and vitamin B6), transplantation (e.g., bone marrow), and immunizations (e.g., prophylactic and therapeutic vaccines) to control immune responses in diverse direction. For example, immunotherapy works to upregulate or downregulate the immune system to achieve a therapeutic effect in immunological mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy.
Clinicians describe the use of immunotherapy in some essential disorders of the immune system. The use of immunoglobulins, transfer factor, immunosuppressors, monoclonal antibodies, cytokines, nutritional supplements, transplantation, among other therapies, is listed below.
- X- linked agammaglobulinemia
- Transient hypogammaglobulinemia of infancy
- Variable common immunodeficiency
- Selective immunoglobulin deficiencies, except for IgA
- Hyper-IgM syndrome
- Lupus-like syndromes
Use of Transfer Factor (Dialysable Leukocyte Extract)
- Interstitial pneumonia in acquired immunodeficient states
- Recurrent viral infections in immunodeficiency syndromes
- Chronic mucocutaneous candidiasis
- Primary tuberculosis with immunodeficiency
- Wiskott-Aldrich syndrome
- Severe combined immunodeficiency disease
- Chronic active hepatitis
- Behcet disease
- Aphthous stomatitis
- Familial keratoacanthoma
Use of Immunosuppressors
- Systemic lupus erythematosus (SLE)
- Wiskott-Aldrich syndrome
- Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
- Autoimmune lymphoproliferative syndrome
- Idiopathic CD4+ lymphocytopenia
- Complement system deficiencies
- Various malignancies
Bone marrow transplant
- RAG-1/RAG-2 SCID
- Artemis SCID
- Wiskott-Aldrich syndrome
- X-linked agammaglobulinemia
- Acute leukemia
- Diphtheria, tetanus, and pertussis (DTP)
- Inactivated Polio vaccine
- Measles, Mumps, and Rubella
- Pneumococcal conjugate
- Hemophilus B conjugate
- Hepatitis B
- Bacille Calmette-Guerin (BCG)
- Human Papillomavirus (HPV)
- Meningococcal vaccine
- Cholera vaccine
- Rotavirus vaccine
- Yellow fever vaccine
- Dengue vaccine
Use of Cytokines in the Immunotherapy of Advanced Malignancies
Use of Nutritional Supplements (Vitamins A, C, E and B6, Iron, Zinc, Selenium, and Copper)
- Primary immunodeficiency with malnutrition
- Malignancies in general
- Graft-versus-host reaction
- Diseases with impaired cell-mediated immunity
- Recurrent and chronic bacterial infections
Phase III Clinical Trials of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib
- Relapsed or refractory chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Relapsed or refractory Mantle cell lymphoma
- Newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma
Use of Interferon Gamma
- Chronic granulomatous disease
- Bladder carcinoma
- Chagas disease
- Lepromatous leprosy
- Cryptococcal meningitis
Immune Checkpoint Inhibitors
Cytokine Antagonists (IL-1RA)
- Septic shock
- Inflammatory bowel disease
- Ischemia-reperfusion injury
- Adult respiratory distress syndrome
- Polyarteritis nodosa
Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)
- Accelerate marrow recovery after autologous bone marrow transplantation
- Primary neutropenia
- Myeloproliferative disorders
- Aplastic anemia
- Neutropenia associated with Felty syndrome
Mechanism of Action
Intravenous Immunoglobulins (IVIG)
IVIG is a product made from fractionation pools of thousands of plasma donations collected in blood transfusion services. Traces of IgM and IgA and cytokines are present in IVIG. IVIGs have several proposed mechanisms of actions to achieve their therapeutic effects, including:
- Effects of IVIG on activated B lymphocytes
- Infusion of IVIG results in auto-IgG suppression
- Interaction of Fc fragment with Fc receptors
- Interaction of infused IgG with complement proteins
- Modulation of synthesis of cytokines
- Modulation of cell proliferation and apoptosis
- Neutralizes pathogenic autoantibodies
- Interferes with antigen presentation
- Functional blockade of Fc receptors on splenic macrophages
- Selection of immune repertoires
- Neutralization of bacterial toxins and superantigens
- Hindrance of natural killer cell activity
- Inhibition of matrix metalloproteinase-9
- Suppression of NF-kB activation and IkB degradation
- G1 cell cycle arrest
- Prevention of tumor growth
- Enhances the expansion of Tregs
IVIG has been used with some success to improve the symptoms and clinical signs of immune thrombocytopenic purpura (ITP), Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, Systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies, ANCA-associated vasculitis, multiple motor neuropathy, multiple sclerosis, Myasthenia gravis, Kawasaki disease, autoimmune uveitis, dermatomyositis, systemic sclerosis, Sjogren syndrome, antiphospholipid antibody syndrome, Still disease, acute disseminated encephalomyelitis, diabetic neuropathy, Lambert-Eaton myasthenic syndrome, Opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen encephalitis, Stiff person syndrome, primary immunodeficiency disorders, secondary immunodeficiency disorder, chronic lymphocytic leukemia, bone marrow transplantation, Treatment-induced neutropenia and thrombocytopenia, AIDS, autoimmune thyroiditis, inclusion-body myositis, graft versus host disease, recurrent pregnancy loss, cancer, severe infections, toxic epidermal necrolysis, Stevens-Johnson syndrome, and neonatal hemochromatosis.
It is a dialysable extract of leukocytes and can transfer cell-mediated immunity from one individual to another. It may use in several pathologies, including immunodeficiencies, viral infections, malignancies, and recurrent fungal infections. Some patients with type I hypersensitivity disorders have reacted to this product.
Steroids inhibit cytokine synthesis, affect cell migration, and inhibit the production of leukocytes. Cyclophosphamide acts by covalent alkylation, together with chlorambucil, exert an immunomodulatory effect. They inhibit strand separation of DNA during replication. Methotrexate is an analog of folic acid and blocks pathways essential for DNA synthesis. Azathioprine is a drug that can convert to 6-mercaptopurine, and its effect is incorporation into DNA as a fraudulent base.
It is a promising solution for many rare diseases that can manifest as primary immunodeficiencies, including severe-combined immunodeficiency disorder (SCID), DiGeorge syndrome, Wiskott-Aldrich syndrome, and X-linked agammaglobulinemia.
Several Immunotherapy Modalities Used in Cancer Treatment
The use of monoclonal antibodies can use in cancer immunotherapy, for example, immune checkpoint inhibitors (ICIs), including pembrolizumab and atezolizumab. These ICI unlock the immune system, which is then able to recognize tumors and kill them.
The use of cytokines to successfully treat certain malignancies is a reality; for example, IL-2 combined with interferon-gamma for renal carcinoma, interferon-alpha and beta for hairy leukemia, and TNF-alpha used in various tumors caused a notable reduction of the mass. These cytokines upregulated the immune system by stimulating T cell and NK cell activation and increased MHC class I expression.
IVIG can administer intravenously in the dosage of 0.4 g/kg for five days to treat Guillain–Barre syndrome, but the dose varies depending on the pathology. Cyclophosphamide low dose has had a more significant impact on cell-mediated immunity. In humans, a low-dose bolus 600 mg/m B cells decrease more than T cells, and among T cells, the CD8 subset diminishes more than CD4 cells.
Patients with T-cell deficiencies, including SCID, should not vaccinate with the live-attenuated vaccine because there is a danger that the antigen reverses its pathogenicity and causes physical illness. Patients with IgA deficiency should not receive IgG preparations that are not highly purified because there is a danger of a hypersensitivity reaction. If the immune system does not recognize the IgA in the preparation, this can be life-threatening. Patients with DiGeorge syndrome should not be transplanted with a thymus older than 14 weeks because a graft-versus-host reaction may occur. The donor can be one of the siblings or a parent if genetic compatibility exists. Blood group compatibility for major antigens such as the ABO system and Rh system must match.
Enhancing Healthcare Team Outcomes
The use of IVIG has expanded significantly over the past three decades. In general, the management of patients with immune deficits is best with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists. While IVIG is effective, patients need to understand that the therapy is not benign and is associated with adverse effects. Close monitoring of patients is necessary because of allergies, anaphylaxis, and graft versus host reactions. Given the potential for adverse events with immunotherapy, the entire team must be vigilant for these reactions. The pharmacist must have close involvement with nursing and the clinician staff, with all members of the interprofessional team informed and communicating regarding the adverse event profile, so immunotherapy has the best chance to help the patient with minimal chance for deleterious effects. [Level 5]